Liraglutide vs Semaglutide
Saxenda, VictozavsOzempic, Wegovy, Rybelsus
Liraglutide (sold as Saxenda and Victoza) and semaglutide (sold as Ozempic and Wegovy) are both GLP-1 receptor agonist therapies used for type 2 diabetes and weight management; liraglutide is administered once daily, while semaglutide is available as a once-weekly injectable or a daily oral tablet.
Vial summary · compiled from public records
At a glance
Liraglutide
Sold as Saxenda, Victoza
- Category
- Metabolic
- FDA / legal status
- FDA Approved
- Route
- Subcutaneous
Semaglutide
Sold as Ozempic, Wegovy, Rybelsus
- Category
- Weight Loss
- FDA / legal status
- Restricted
- Route
- Subcutaneous, oral
Side by side
| Field | Liraglutide | Semaglutide |
|---|---|---|
| Category | Metabolic | Weight Loss |
| Brand names | Saxenda, Victoza | Ozempic, Wegovy, Rybelsus |
| FDA / legal status | FDA Approved | Restricted |
| Evidence tier | Clinical Trials | FDA Approved |
| Administration route | Subcutaneous | Subcutaneous, oral |
| Compounding access | FDA-approved product, dispensed by prescription | Restricted |
| Providers on Vial | 0 listed | 28 listed |
| Typical price band | Varies by provider | $ to $$ |
Verified providers offering each
Ranked by Vial Score, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
Liraglutide0 top providers
No surfaceable providers currently list Liraglutide on Vial.
See all 0 providers offering liraglutide →About each compound
About Liraglutide
Liraglutide is a once-daily GLP-1 receptor agonist marketed as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first GLP-1 agents to demonstrate meaningful weight loss in clinical trials, producing 5–8% body weight reduction on average. Though largely superseded by weekly agents, it remains a clinically validated option. Compounded liraglutide is available through select pharmacies.
About Semaglutide
A synthetic glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide mimics the incretin hormone GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. The compound also acts on hypothalamic receptors to reduce appetite and food intake. Primary clinical applications include the management of type 2 diabetes mellitus and chronic weight management in individuals with obesity or overweight with weight-related comorbidities.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.